General Principles | p. 1 |
Information, Sources, and Regulatory Agencies | p. 2 |
History | p. 2 |
Pharmacology and the Oral Health Care Providers | p. 3 |
Sources of Information | p. 4 |
Explain-Discuss Format | p. 4 |
Reference-List Format | p. 5 |
Types of Media | p. 5 |
Drug Names | p. 7 |
Drug Substitution | p. 10 |
Top 200 Drugs | p. 10 |
Federal Regulatory Agencies | p. 10 |
Harrison Narcotic Act | p. 10 |
Food and Drug Administration | p. 11 |
Federal Trade Commission | p. 11 |
Drug Enforcement Administration | p. 11 |
Omnibus Budget Reconciliation Act | p. 11 |
Drug Action and Handling | p. 12 |
Characterization of Drug Action | p. 13 |
Log Dose Effect Curve | p. 13 |
Potency | p. 13 |
Efficacy | p. 14 |
Chemical Signaling between Cells | p. 15 |
Mechanism of Action of Drugs | p. 15 |
Nerve Transmission | p. 16 |
Receptors | p. 17 |
Stereoisomerism | p. 21 |
Routes of Administration and Dose Forms | p. 21 |
Routes of Administration | p. 21 |
Dose Forms | p. 26 |
Pharmacokinetics | p. 26 |
Passage across Body Membranes | p. 26 |
Absorption | p. 29 |
Distribution | p. 30 |
Half-Life | p. 31 |
Blood-Brain Barrier | p. 32 |
Redistribution | p. 33 |
Metabolism (Biotransformation) | p. 33 |
Factors that Alter Drug Effects | p. 38 |
Calculation of Children's Dose | p. 39 |
Adverse Reactions | p. 41 |
Definitions and Classifications | p. 41 |
Clinical Manifestations of Adverse Reactions | p. 42 |
Exaggerated Effect on Target Tissues | p. 43 |
Effect on Nontarget Tissues | p. 43 |
Effect on Fetal Development (Teratogenic Effect) | p. 43 |
Local Effect | p. 44 |
Drug Interactions | p. 44 |
Hypersensitivity (Allergic Reaction) | p. 44 |
Idiosyncrasy | p. 45 |
Interference with Natural Defense Mechanisms | p. 46 |
Toxicologic Evaluation of Drugs | p. 46 |
Prescription Writing | p. 49 |
Measurement | p. 49 |
Metric System | p. 49 |
Household Measures | p. 50 |
Prescriptions | p. 51 |
Format | p. 51 |
Explanations Accompanying Prescriptions | p. 54 |
Drug Legislation | p. 54 |
Scheduled Drugs | p. 55 |
Drugs Used in Dentistry | p. 57 |
Autonomic Drugs | p. 58 |
Autonomic Nervous System | p. 58 |
Anatomy | p. 58 |
Parasympathetic Autonomic Nervous System | p. 59 |
Sympathetic Autonomic Nervous System | p. 59 |
Functional Organization | p. 60 |
Neurotransmitters | p. 60 |
Drug Groups | p. 63 |
Parasympathetic Autonomic Nervous System | p. 64 |
Cholinergic (Parasympathomimetic) agents | p. 66 |
Anticholinergic (Parasympatholytic) agents | p. 68 |
Nicotinic Agonists and Antagonists | p. 71 |
Sympathetic Nervous System | p. 71 |
Sympathetic Nervous System Receptors | p. 72 |
Adrenergic (Sympathomimetic) Agents | p. 73 |
Adrenergic Blocking Agents | p. 77 |
Neuromuscular Blocking Drugs | p. 79 |
Nonopioid (Nonnarcotic) Analgesics | p. 81 |
Pain | p. 81 |
Classification | p. 82 |
Salicylates | p. 83 |
Acetylsalicylic Acid | p. 83 |
Other Salicylates | p. 90 |
Nonsteroidal Antiinflammatory Drugs | p. 92 |
Chemical Classification | p. 92 |
Mechanism of Action | p. 93 |
Pharmacokinetics | p. 93 |
Pharmacologic Effects | p. 94 |
Adverse Reactions | p. 94 |
Contraindications and Cautions | p. 95 |
Therapeutic Uses | p. 95 |
Specific Nonsteroidal Antiinflammatory Drugs | p. 96 |
Acetaminophen | p. 98 |
Pharmacokinetics | p. 99 |
Pharmacologic Effects | p. 99 |
Adverse Effects | p. 99 |
Drug Interactions | p. 100 |
Uses | p. 100 |
Dose and Preparations | p. 100 |
Drugs Used to Treat Gout | p. 101 |
Colchicine | p. 101 |
Allopurinol | p. 101 |
Probenecid | p. 102 |
Opioid (Narcotic) Analgesics and Antagonists | p. 103 |
History | p. 103 |
Terminology | p. 103 |
Classification | p. 104 |
Mechanism of Action | p. 104 |
Pharmacokinetics | p. 106 |
Pharmacologic Effects | p. 107 |
Analgesia | p. 107 |
Sedation and Euphoria | p. 108 |
Cough Suppression | p. 108 |
Gastrointestinal Effects | p. 108 |
Adverse Reactions | p. 108 |
Respiratory Depression | p. 108 |
Nausea and Emesis | p. 109 |
Constipation | p. 109 |
Myosis | p. 109 |
Urinary Retention | p. 109 |
Central Nervous System Effects | p. 109 |
Cardiovascular Effects | p. 109 |
Biliary Tract Constriction | p. 109 |
Histamine Release | p. 109 |
Pregnancy and Nursing | p. 109 |
Addiction | p. 109 |
Treatment | p. 110 |
Allergic Reactions | p. 110 |
Drug Interactions | p. 111 |
Specific Opioids | p. 112 |
Opioid Agonists | p. 112 |
Mixed Opioids | p. 115 |
Tramadol | p. 116 |
Dental Use of Opioids | p. 117 |
Antiinfective Agents | p. 119 |
Dental Infection "Evolution" | p. 120 |
History | p. 122 |
Definitions | p. 122 |
Culture and Sensitivity | p. 124 |
Culture | p. 124 |
Sensitivity | p. 124 |
Indications for Antimicrobial Agents | p. 125 |
Therapeutic Indications | p. 125 |
Prophylactic Indications | p. 125 |
General Adverse Reactions Associated with Antiinfective Agents | p. 127 |
Superinfection (Suprainfection) | p. 127 |
Allergic Reactions | p. 127 |
Drug Interactions | p. 127 |
Gastrointestinal Complaints | p. 128 |
Pregnancy | p. 128 |
Dose Forms | p. 128 |
Cost | p. 129 |
Penicillins | p. 129 |
Source and Chemistry | p. 130 |
Pharmacokinetics | p. 130 |
Mechanism of Action | p. 131 |
Spectrum | p. 131 |
Resistance | p. 131 |
Adverse Reactions | p. 132 |
Allergy and Hypersensitivity | p. 132 |
Uses | p. 133 |
Specific Penicillins | p. 133 |
Macrolides | p. 135 |
Erythromycin | p. 136 |
Azithromycin and Clarithromycin | p. 137 |
Tetracyclines | p. 138 |
Pharmacokinetics | p. 139 |
Spectrum | p. 139 |
Adverse Reactions | p. 139 |
Drug Interactions | p. 140 |
Uses | p. 141 |
Clindamycin | p. 142 |
Pharmacokinetics | p. 142 |
Spectrum | p. 142 |
Adverse Reactions | p. 142 |
Uses | p. 143 |
Metronidazole | p. 144 |
Pharmacokinetics | p. 144 |
Spectrum | p. 144 |
Adverse Reactions | p. 144 |
Drug Interactions | p. 145 |
Uses | p. 145 |
Cephalosporins | p. 145 |
Pharmacokinetics | p. 147 |
Spectrum | p. 147 |
Mechanism of Action | p. 147 |
Adverse Reactions | p. 147 |
Uses | p. 148 |
Rational Use of Antiinfective Agents in Dentistry | p. 148 |
p. 148 | |
p. 149 | |
p. 149 | |
Antimicrobial Agents for Nondental Use | p. 149 |
Vancomycin | p. 149 |
Aminoglycosides | p. 150 |
Chloramphenicol | p. 151 |
Sulfonamides | p. 151 |
Sulfamethoxazole-trimethoprim | p. 152 |
Nitrofurantoin | p. 152 |
Quinolones (Fluoroquinolones) | p. 152 |
Antituberculosis Agents | p. 154 |
Isoniazid | p. 154 |
Rifampin | p. 156 |
Pyrazinamide | p. 156 |
Ethambutol | p. 157 |
Topical Antibiotics | p. 157 |
Neomycin, Polymyxin, and Bacitracin | p. 157 |
Mupirocin | p. 157 |
Antibiotic Prophylaxis Used in Dentistry | p. 158 |
Prevention of Infective Endocarditis | p. 158 |
Prosthetic Joint Prophylaxis | p. 161 |
Noncardiac Medical Conditions | p. 161 |
Antifungal and Antiviral Agents | p. 163 |
Antifungal Agents | p. 163 |
Nystatin | p. 165 |
Imidazoles | p. 167 |
Other Antifungal Agents | p. 169 |
Antiviral Agents | p. 170 |
Herpes Simplex | p. 171 |
Acquired Immunodeficiency Syndrome | p. 173 |
Local Anesthetics | p. 177 |
History | p. 177 |
Ideal Local Anesthetic | p. 178 |
Chemistry | p. 178 |
Mechanism of Action | p. 179 |
Action on Nerve Fibers | p. 179 |
Ionization Factors | p. 179 |
Pharmacokinetics | p. 179 |
Absorption | p. 179 |
Distribution | p. 182 |
Metabolism | p. 182 |
Excretion | p. 182 |
Pharmacologic Effects | p. 182 |
Peripheral Nerve Conduction (Blocker) | p. 182 |
Antiarrhythmic | p. 183 |
Adverse Reactions | p. 183 |
Composition of Local Anesthetic Solutions | p. 185 |
Local Anesthetic Agents | p. 185 |
Amides | p. 185 |
Esters | p. 189 |
Other Local Anesthetics | p. 189 |
Vasoconstrictors | p. 189 |
Drug Interactions | p. 192 |
Choice of Local Anesthetic | p. 192 |
Topical Anesthetics | p. 193 |
Amides | p. 195 |
Esters | p. 196 |
Precautions in Topical Anesthesia | p. 197 |
Doses of Local Anesthetic and Vasoconstrictor | p. 197 |
Antianxiety Agents | p. 199 |
Definitions | p. 201 |
Benzodiazepines | p. 201 |
Chemistry | p. 201 |
Pharmacokinetics | p. 201 |
Mechanism of Action | p. 204 |
Pharmacologic Effects | p. 204 |
Adverse Reactions | p. 205 |
Abuse and Tolerance | p. 207 |
Drug Interactions | p. 208 |
Uses | p. 208 |
Management of the Dental Patient Taking Benzodiazepines | p. 210 |
Barbiturates | p. 211 |
Chemistry | p. 211 |
Pharmacokinetics | p. 211 |
Mechanism of Action | p. 212 |
Pharmacologic Effects | p. 212 |
Adverse Reactions | p. 212 |
Chronic Long-Term Use | p. 212 |
Contraindications | p. 213 |
Drug Interactions | p. 213 |
Uses | p. 213 |
Nonbenzodiazepine-nonbarbiturate sedative-hypnotics | p. 213 |
Chloral Hydrate | p. 213 |
Buspirone | p. 214 |
Meprobamate | p. 214 |
Nonbenzodiazepine Benzodiazepine Receptor Agonists | p. 215 |
Zolpidem | p. 215 |
Zaleplon | p. 215 |
Eszopiclone | p. 215 |
Melatonin Receptor Agonist | p. 216 |
Centrally Acting Muscle Relaxants | p. 216 |
Pharmacologic Effects | p. 216 |
Individual Centrally Acting Muscle Relaxants | p. 216 |
Miscellaneous Agents | p. 217 |
Baclofen | p. 217 |
Tizanidine | p. 217 |
Dantrolene | p. 217 |
General Comments about Antianxiety Agents | p. 217 |
Analgesic-Sedative Combinations | p. 217 |
Special Considerations | p. 218 |
Cautions | p. 218 |
General Anesthetics | p. 220 |
History | p. 220 |
Mechanism of Action | p. 221 |
Stages and Planes of Anesthesia | p. 221 |
Adverse Reactions | p. 223 |
General Anesthetics | p. 223 |
Classification of Anesthetic Agents | p. 223 |
Nitrous Oxide | p. 225 |
Halogenated Hydrocarbons | p. 229 |
Other General Anesthetics | p. 231 |
Balanced General Anesthesia | p. 233 |
Vitamins and Minerals | p. 234 |
Measurements of Vitamin Needs | p. 234 |
Recommended Dietary Allowance | p. 234 |
Fallacious Reasoning about Vitamins | p. 236 |
Water-Soluble Vitamins | p. 236 |
Ascorbic Acid (Vitamin C) | p. 236 |
B-Complex Vitamins | p. 238 |
Fat-Soluble Vitamins | p. 247 |
Vitamin A | p. 247 |
Vitamin D | p. 249 |
Vitamin E | p. 251 |
Vitamin K | p. 252 |
Selected Minerals | p. 253 |
Iron | p. 253 |
Zinc | p. 254 |
Calcium | p. 255 |
Drug-Induced Vitamin Deficiencies | p. 256 |
Oral Conditions and Their Treatment | p. 258 |
Infectious Lesions | p. 258 |
Acute Necrotizing Ulcerative Gingivitis | p. 258 |
Herpes Infections | p. 259 |
Candidiasis (Moniliasis) | p. 261 |
Angular Cheilitis/Cheilosis | p. 261 |
Alveolar Osteitis | p. 262 |
Immune Reactions | p. 262 |
Recurrent Aphthous Stomatitis | p. 262 |
Lichen Planus | p. 263 |
Miscellaneous Oral Conditions | p. 264 |
Geographic Tongue | p. 264 |
Burning Mouth or Tongue Syndrome | p. 264 |
Inflammation | p. 265 |
Pericoronitis | p. 265 |
Postirradiation Caries | p. 265 |
Root Sensitivity | p. 265 |
Actinic Lip Changes | p. 265 |
Drug-Induced Oral Side Effects | p. 265 |
Xerostomia | p. 265 |
Sialorrhea | p. 268 |
Hypersensitivity-Type Reactions | p. 268 |
Oral Lesions that Resemble Autoimmune-Type Reactions | p. 268 |
Stains | p. 268 |
Gingival Enlargement | p. 268 |
Common Agents Used to Treat Oral Lesions | p. 269 |
Corticosteroids | p. 269 |
Palliative Treatment | p. 270 |
Drugs That May Alter Dental Treatment | p. 271 |
Cardiovascular Drugs | p. 272 |
Dental Implications of Cardiovascular Disease | p. 273 |
Contraindications to Treatment | p. 273 |
Vasoconstrictor Limit | p. 273 |
Infective Endocarditis | p. 273 |
Cardiac Pacemakers | p. 274 |
Periodontal Disease and Cardiovascular Disease | p. 274 |
Cardiac Glycosides | p. 274 |
Congestive Heart Failure | p. 274 |
Digitalis Glycosides | p. 275 |
Antiarrhythmic Agents | p. 277 |
Automaticity | p. 277 |
Action Potential | p. 279 |
Arrhythmias | p. 279 |
Antiarrhythmic agents | p. 279 |
Adverse Reactions | p. 281 |
Dental Implications | p. 281 |
Antianginal Drugs | p. 281 |
Angina Pectoris | p. 281 |
Nitroglycerin-like Compounds | p. 282 |
Calcium Channel Blocking Agents | p. 285 |
[Beta]-Adrenergic Blocking Agents | p. 286 |
Ranolazine | p. 286 |
Dental Implications | p. 286 |
Antihypertensive Agents | p. 287 |
Patient Evaluation | p. 289 |
Treatment of Hypertension | p. 289 |
Diuretic Agents | p. 292 |
[Beta]-Adrenergic Blocking Agents | p. 296 |
Calcium Channel Blocking Agents | p. 297 |
Angiotensin-Related Agents | p. 299 |
[alpha subscript 1]-Adrenergic Blocking Agents | p. 301 |
Other Antihypertensive Agents | p. 302 |
Management of the Dental Patient Taking Antihypertensive Agents | p. 303 |
Antihyperlipidemic Agents | p. 304 |
3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors | p. 304 |
Niacin | p. 305 |
Cholestyramine | p. 306 |
Gemfibrozil | p. 306 |
Dental Implications | p. 306 |
Drugs that Affect Blood Coagulation | p. 306 |
Anticoagulants | p. 306 |
Drugs that Increase Blood Clotting | p. 312 |
Anticonvulsants | p. 314 |
Epilepsy | p. 314 |
Generalized Seizures | p. 314 |
Partial (Focal) Epilepsies | p. 317 |
Drug Therapy of Patients with Epilepsy | p. 317 |
General Adverse Reactions to Anticonvulsant Agents | p. 317 |
Carbamazepine | p. 319 |
Valproate | p. 320 |
Phenobarbital | p. 321 |
Phenytoin | p. 321 |
Miscellaneous Anticonvulsant Agents | p. 323 |
New Anticonvulsant Agents | p. 323 |
Dental Treatment of the Patient with Epilepsy | p. 323 |
Nonseizure Uses of Anticonvulsants | p. 325 |
Neurologic Pain | p. 325 |
Psychiatric Use | p. 325 |
Psychotherapeutic Agents | p. 326 |
Psychiatric Disorders | p. 326 |
Antipsychotic Agents | p. 328 |
Pharmacologic Effects | p. 329 |
Adverse Reactions | p. 330 |
Drug Interactions | p. 332 |
Uses | p. 332 |
Dental Implications | p. 332 |
Antidepressant Agents | p. 333 |
Tricyclic Antidepressants | p. 333 |
Second-Generation Antidepressants | p. 336 |
Selective Serotonin Reuptake Inhibitors | p. 336 |
Bupropion | p. 337 |
Other Antidepressant Agents | p. 337 |
Monoamine Oxidase Inhibitors | p. 337 |
Drugs for Treatment of Bipolar Depression | p. 338 |
Lithium | p. 338 |
Anticonvulsants | p. 338 |
Autocoids and Antihistamines | p. 339 |
Histamine | p. 339 |
Pharmacologic Effects | p. 339 |
Adverse Reactions | p. 340 |
Uses | p. 340 |
Antihistamines (H[subscript 1]-Receptor Antagonists) | p. 340 |
Pharmacologic Effects | p. 341 |
Adverse Reactions | p. 341 |
Toxicity | p. 343 |
Uses | p. 344 |
Peripheral (Nonsedating) H[subscript 1]-Receptor Antagonists | p. 344 |
Fexofenadine | p. 344 |
Loratidine | p. 345 |
Cetirizine | p. 345 |
Other Autocoids | p. 345 |
Prostaglandins and Thromboxanes | p. 345 |
Leukotrienes | p. 347 |
Kinins | p. 347 |
Substance P | p. 347 |
Adrenocorticosteroids | p. 349 |
Mechanism of Release | p. 349 |
Classification | p. 350 |
Definitions | p. 350 |
Routes of Administration | p. 350 |
Mechanism of Action | p. 351 |
Pharmacologic Effects | p. 351 |
Adverse Reactions | p. 352 |
Metabolic Changes | p. 352 |
Infections | p. 352 |
Central Nervous System Effects | p. 352 |
Peptic Ulcer | p. 352 |
Impaired Wound Healing and Osteoporosis | p. 352 |
Ophthalmic Effects | p. 352 |
Electrolyte and Fluid Balance | p. 352 |
Adrenal Crisis | p. 353 |
Dental Effects | p. 353 |
Uses | p. 353 |
Medical Uses | p. 353 |
Dental Uses | p. 354 |
Corticosteroid Products | p. 354 |
Dental Implications | p. 354 |
Adverse Reactions | p. 355 |
Steroid Supplementation | p. 356 |
Rule of Twos | p. 357 |
Topical Use | p. 357 |
Other Hormones | p. 359 |
Pituitary Hormones | p. 359 |
Anterior Pituitary | p. 360 |
Posterior Pituitary | p. 361 |
Thyroid Hormones | p. 361 |
Iodine | p. 361 |
Hypothyroidism | p. 362 |
Hyperthyroidism | p. 362 |
Pancreatic Hormones | p. 363 |
Diabetes Mellitus | p. 363 |
Female Sex Hormones | p. 375 |
Estrogens | p. 376 |
Progestins | p. 377 |
Oral Contraceptives | p. 378 |
Male Sex Hormones | p. 380 |
Androgens | p. 380 |
Other Agents that Affect Sex Hormone Systems | p. 381 |
Clomiphene | p. 382 |
Leuprolide | p. 382 |
Tamoxifen | p. 382 |
Danazol | p. 382 |
Aromatase Inhibitors | p. 382 |
Antineoplastic Drugs | p. 384 |
Use of Antineoplastic Agents | p. 385 |
Mechanisms of Action | p. 385 |
Classification | p. 387 |
Adverse Drug Effects | p. 387 |
Bone Marrow Suppression | p. 387 |
Osteonecrosis | p. 389 |
Gastrointestinal Effects | p. 390 |
Dermatologic Effects | p. 390 |
Hepatotoxicity | p. 390 |
Neurologic Effects | p. 390 |
Nephrotoxicity | p. 390 |
Immunosuppression | p. 390 |
Germ Cells | p. 390 |
Oral Effects | p. 390 |
Combinations | p. 390 |
Use in Treatment of Inflammatory Processes | p. 391 |
Dental Implications | p. 391 |
Respiratory and Gastrointestinal Drugs | p. 393 |
Respiratory Drugs | p. 393 |
Respiratory Diseases | p. 393 |
Drugs Used to Treat Respiratory Diseases | p. 395 |
Sympathomimetic Agents | p. 395 |
Metered-Dose Inhalers | p. 396 |
Corticosteroids | p. 396 |
Leukotriene-Pathway Inhibitors | p. 399 |
Methylxanthines | p. 400 |
Anticholinergics | p. 400 |
Agents Used to Manage Upper Respiratory Infections | p. 400 |
Dental Implications of the Respiratory Drugs | p. 401 |
Gastrointestinal Drugs | p. 402 |
Gastrointestinal Diseases | p. 402 |
Drugs Used to Treat Gastrointestinal Diseases | p. 402 |
Histamine[subscript 2]-Blocking Agents | p. 402 |
Proton Pump Inhibitors | p. 404 |
Mixed Antiinfective Therapy for Ulcer Treatment | p. 405 |
Antacids | p. 405 |
Miscellaneous Gastrointestinal Drugs | p. 405 |
Laxatives and Antidiarrheals | p. 406 |
Emetics and Antiemetics | p. 406 |
Agents Used to Manage Chronic Inflammatory Bowel Disease | p. 407 |
Special Situations | p. 409 |
Emergency Drugs | p. 410 |
General Measures | p. 410 |
Preparation for Treatment | p. 411 |
Categories of Emergencies | p. 411 |
Lost or Altered Consciousness | p. 411 |
Respiratory Emergencies | p. 412 |
Cardiovascular System Emergencies | p. 413 |
Other Emergency Situations | p. 414 |
Drug-Related Emergencies | p. 415 |
Emergency Kit for the Dental Office | p. 415 |
Drugs | p. 415 |
Equipment | p. 418 |
Pregnancy and Breast Feeding | p. 420 |
General Principles | p. 421 |
History | p. 421 |
Pregnancy | p. 421 |
Pregnancy Trimesters | p. 421 |
Teratogenicity | p. 421 |
Food and Drug Administration Pregnancy Categories | p. 422 |
Breast Feeding | p. 422 |
Dental Drugs | p. 422 |
Local Anesthetic Agents | p. 422 |
Analgesics | p. 428 |
Antiinfective Agents | p. 428 |
Antianxiety Agents | p. 429 |
Drug Interactions | p. 431 |
Mechanisms of Interactions | p. 431 |
Pharmacokinetic | p. 432 |
Pharmacodynamic | p. 433 |
Dental Drug Interactions | p. 434 |
Analgesics | p. 436 |
Antiinfectives | p. 438 |
Benzodiazepines | p. 439 |
Epinephrine | p. 439 |
Summary | p. 441 |
Drug Abuse | p. 443 |
General Considerations | p. 444 |
Definitions | p. 444 |
Psychologic Dependence | p. 445 |
Physical Dependence | p. 445 |
Tolerance | p. 445 |
Addiction, Habituation, and Dependence | p. 446 |
Central Nervous System Depressants | p. 446 |
Ethyl Alcohol | p. 447 |
Nitrous Oxide | p. 450 |
Opioid Analgesics | p. 451 |
Sedative-Hypnotics | p. 453 |
Central Nervous System Stimulants | p. 454 |
Cocaine | p. 454 |
Amphetamines | p. 455 |
Caffeine | p. 455 |
Tobacco | p. 455 |
Psychedelics (Hallucinogens) | p. 457 |
Lysergic Acid Diethylamide | p. 457 |
Phencyclidine | p. 457 |
Marijuana | p. 458 |
Identifying the Drug Abuser | p. 458 |
The Impaired Dental Health Care Worker | p. 458 |
Appendixes | |
Top 200 Drugs (2005) | p. 460 |
Medical Acronyms | p. 466 |
Medical Terminology | p. 470 |
What If... | p. 472 |
Oral Manifestations: Xerostomia and Taste Changes | p. 480 |
Natural/Herbal Products | p. 484 |
Glossary | p. 489 |
Drug Index | p. 510 |
Index | p. 522 |
Table of Contents provided by Ingram. All Rights Reserved. |
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.